Pharma Times -- Bayer has signed a deal with EndoCeutics, giving the German group rights to Vaginorm, an investigational treatment for vaginal atrophy and female sexual dysfunction. Vaginorm, an intra-vaginal application of the hormone dehydroepiandrosterone, is in a Phase III clinical programme and Bayer says research has shown that one quarter to one-half of postmenopausal women suffer from vaginal atrophy, tissue changes that can cause dryness, itching, burning and painful sex.
